Aurora Cannabis Inc. (ACB)
NASDAQ • Healthcare
October 13, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 21 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Aurora Cannabis’s revenue fell 23% to roughly CAD 67.6 million from about CAD 88.2 million a year ago in the first fiscal quarter of 2027, reported on August 5 based on preliminary results. Operating cash flow was negative roughly CAD 4.4 million. Consensus for the next period calls for EPS of CAD -0.09.
Next report — what to expect
Aurora Cannabis Inc (ACB) is set to report on November 4, 2026. Wall Street consensus calls for EPS of -CAD 0.03 on revenue of CAD 50.7 million. For trailing context, revenue fell -23.4% year over year last quarter. Aurora has beaten EPS in 3 of its 8 most recent quarters.
About Aurora Cannabis Inc.
Aurora Cannabis Inc. (NASDAQ: ACB) develops, cultivates, produces, and sells cannabis and cannabis-derived products for the healthcare market, with operations centered on medical users in Canada and abroad through wholesale and retail channels. In FY2026, the company generated CAD 321.4 million in revenue.
Today's Snapshot
ACB closed 1.4% lower at 4.29. Aurora Cannabis reported CA$67.554 million in Q1 2027 revenue and a smaller loss than a year earlier.
Trading Volume
Below 10d avg (1.5M)
624.1K
vs S&P 500 Today
Underperforming Market
-1.36%
Updated: October 14, 2026 at 12:28 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$3.69 - $4.31Buy
- RSI (14)57.26Neutral
- Stochastic %K (14, 3, 3)65.49Neutral
- MACD Level (12, 26)0.16Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.